186 related articles for article (PubMed ID: 16622681)
41. CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells.
Olson BM; McNeel DG
Cancer Immunol Immunother; 2011 Jun; 60(6):781-92. PubMed ID: 21350948
[TBL] [Abstract][Full Text] [Related]
42. Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1
Shenderov E; Kandasamy M; Gileadi U; Chen J; Shepherd D; Gibbs J; Prota G; Silk JD; Yewdell JW; Cerundolo V
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088742
[TBL] [Abstract][Full Text] [Related]
43. Identification of human MHC-I HPV18 E6/E7-specific CD8 + T cell epitopes and generation of an HPV18 E6/E7-expressing adenosquamous carcinoma in HLA-A2 transgenic mice.
Peng S; Xing D; Ferrall L; Tsai YC; Hung CF; Wu TC
J Biomed Sci; 2022 Oct; 29(1):80. PubMed ID: 36224625
[TBL] [Abstract][Full Text] [Related]
44. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer.
Yoshino I; Goedegebuure PS; Peoples GE; Parikh AS; DiMaio JM; Lyerly HK; Gazdar AF; Eberlein TJ
Cancer Res; 1994 Jul; 54(13):3387-90. PubMed ID: 7912166
[TBL] [Abstract][Full Text] [Related]
45. Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients.
Wilkinson R; Woods K; D'Rozario R; Prue R; Vari F; Hardy MY; Dong Y; Clements JA; Hart DNJ; Radford KJ
Cancer Immunol Immunother; 2012 Feb; 61(2):169-179. PubMed ID: 21874303
[TBL] [Abstract][Full Text] [Related]
46. Identification of a new HLA-A(*)0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen.
Sun Y; Song M; Stevanović S; Jankowiak C; Paschen A; Rammensee HG; Schadendorf D
Int J Cancer; 2000 Aug; 87(3):399-404. PubMed ID: 10897046
[TBL] [Abstract][Full Text] [Related]
47. Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients.
González FE; Ramírez M; Allerbring EB; Fasching N; Lundqvist A; Poschke I; Achour A; Salazar-Onfray F
Immunobiology; 2014 Mar; 219(3):189-97. PubMed ID: 24192537
[TBL] [Abstract][Full Text] [Related]
48. Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design.
Zeng G; Li Y; El-Gamil M; Sidney J; Sette A; Wang RF; Rosenberg SA; Robbins PF
Cancer Res; 2002 Jul; 62(13):3630-5. PubMed ID: 12097265
[TBL] [Abstract][Full Text] [Related]
49. Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells.
Oh S; Terabe M; Pendleton CD; Bhattacharyya A; Bera TK; Epel M; Reiter Y; Phillips J; Linehan WM; Kasten-Sportes C; Pastan I; Berzofsky JA
Cancer Res; 2004 Apr; 64(7):2610-8. PubMed ID: 15059918
[TBL] [Abstract][Full Text] [Related]
50. The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes.
Adair SJ; Carr TM; Fink MJ; Slingluff CL; Hogan KT
J Immunother; 2008 Jan; 31(1):7-17. PubMed ID: 18157007
[TBL] [Abstract][Full Text] [Related]
51. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
[TBL] [Abstract][Full Text] [Related]
52. Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice.
Zhao X; Bose A; Komita H; Taylor JL; Chi N; Lowe DB; Okada H; Cao Y; Mukhopadhyay D; Cohen PA; Storkus WJ
J Immunol; 2012 Feb; 188(4):1782-8. PubMed ID: 22246626
[TBL] [Abstract][Full Text] [Related]
53. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D
Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401
[TBL] [Abstract][Full Text] [Related]
54. Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapy.
Lekka E; Gritzapis AD; Perez SA; Tsavaris N; Missitzis I; Mamalaki A; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2010 May; 59(5):715-27. PubMed ID: 19904532
[TBL] [Abstract][Full Text] [Related]
55. Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein.
Kiessling A; Stevanovic S; Füssel S; Weigle B; Rieger MA; Temme A; Rieber EP; Schmitz M
Br J Cancer; 2004 Mar; 90(5):1034-40. PubMed ID: 14997204
[TBL] [Abstract][Full Text] [Related]
56. Identification of HLA-A*0201-restricted cytotoxic T lymphocyte epitope from TRAG-3 antigen.
Zhu B; Chen Z; Cheng X; Lin Z; Guo J; Jia Z; Zou L; Wang Z; Hu Y; Wang D; Wu Y
Clin Cancer Res; 2003 May; 9(5):1850-7. PubMed ID: 12738743
[TBL] [Abstract][Full Text] [Related]
57. Identification of an HLA-A*0201-restricted CD8+ T-cell epitope SSp-1 of SARS-CoV spike protein.
Wang B; Chen H; Jiang X; Zhang M; Wan T; Li N; Zhou X; Wu Y; Yang F; Yu Y; Wang X; Yang R; Cao X
Blood; 2004 Jul; 104(1):200-6. PubMed ID: 15016646
[TBL] [Abstract][Full Text] [Related]
58. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy.
Ueda R; Ohkusu-Tsukada K; Fusaki N; Soeda A; Kawase T; Kawakami Y; Toda M
Int J Cancer; 2010 Feb; 126(4):919-29. PubMed ID: 19728337
[TBL] [Abstract][Full Text] [Related]
59. Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2.
Wagner C; Neumann F; Kubuschok B; Regitz E; Mischo A; Stevanovic S; Friedrich M; Schmidt W; Rammensee HG; Pfreundschuh M
Cancer Immun; 2003 Dec; 3():18. PubMed ID: 14677925
[TBL] [Abstract][Full Text] [Related]
60. Identification of a novel peptide derived from the M-phase phosphoprotein 11 (MPP11) leukemic antigen recognized by human CD8+ cytotoxic T lymphocytes.
Al Qudaihi G; Lehe C; Dickinson A; Eltayeb K; Rasheed W; Chaudhri N; Aljurf M; Dermime S
Hematol Oncol Stem Cell Ther; 2010; 3(1):24-33. PubMed ID: 20231810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
